Articles
Page 8 of 35
-
Citation: Alzheimer's Research & Therapy 2023 15:36
-
Choroid and choriocapillaris changes in early-stage Parkinson’s disease: a swept-source optical coherence tomography angiography-based cross-sectional study
Citation: Alzheimer's Research & Therapy 2023 15:35 -
Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort
Alzheimer’s disease (AD) is a complex neurodegenerative disorder with β-amyloid pathology as a key underlying process. The relevance of cerebrospinal fluid (CSF) and brain imaging biomarkers is validated in cl...
Citation: Alzheimer's Research & Therapy 2023 15:34 -
Early activation of Toll-like receptor-3 reduces the pathological progression of Alzheimer’s disease in APP/PS1 mouse
Toll-like receptor 3 (TLR3) plays an important role in the immune/inflammatory response in the nervous system and is a main pathological feature of Alzheimer’s disease (AD). This study investigates the role of...
Citation: Alzheimer's Research & Therapy 2023 15:33 -
Neural biomarker diagnosis and prediction to mild cognitive impairment and Alzheimer’s disease using EEG technology
Electroencephalogram (EEG) has emerged as a non-invasive tool to detect the aberrant neuronal activity related to different stages of Alzheimer’s disease (AD). However, the effectiveness of EEG in the precise ...
Citation: Alzheimer's Research & Therapy 2023 15:32 -
The dynamics of plasma biomarkers across the Alzheimer’s continuum
Failures in drug trials strengthen the necessity to further determine the neuropathological events during the development of Alzheimer’s disease (AD). We sought to investigate the dynamic changes and performan...
Citation: Alzheimer's Research & Therapy 2023 15:31 -
Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer’s disease
To better assist with the design of future clinical trials for Alzheimer’s disease (AD) and aid in our understanding of the disease’s symptomatology, it is essential to clarify what roles β-amyloid (Aβ) plaque...
Citation: Alzheimer's Research & Therapy 2023 15:30 -
Correction: Cortical microstructure in primary progressive aphasia: a multicenter study
Citation: Alzheimer's Research & Therapy 2023 15:29 -
Recruitment across two decades of NIH-funded Alzheimer’s disease clinical trials
Timely accrual of a representative sample is a key factor in whether Alzheimer’s disease (AD) clinical trials successfully answer the scientific questions under study. Studies in other fields have observed tha...
Citation: Alzheimer's Research & Therapy 2023 15:28 -
Hippocampus-centred grey matter covariance networks predict the development and reversion of mild cognitive impairment
Mild cognitive impairment (MCI) has been thought of as the transitional stage between normal ageing and Alzheimer’s disease, involving substantial changes in brain grey matter structures. As most previous stud...
Citation: Alzheimer's Research & Therapy 2023 15:27 -
Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy
To evaluate the potential of cerebrospinal fluid (CSF) levels of matrix metalloproteinases and tissue-type inhibitors (MMP; TIMP), and ratios of MMPs to TIMPs, to function as biomarkers for sporadic or heredit...
Citation: Alzheimer's Research & Therapy 2023 15:26 -
Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit
Alzheimer’s disease (AD) is a complex and heterogeneous disease, which requires reliable biomarkers for diagnosis and monitoring disease activity. Preanalytical protocol and technical variability associated wi...
Citation: Alzheimer's Research & Therapy 2023 15:25 -
Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer’s dementia: a randomized controlled trial
This phase II proof-of-concept study assessed the efficacy and safety of BI 425809, a novel selective glycine transporter-1 inhibitor, for the treatment of cognitive impairment associated with probable Alzheim...
Citation: Alzheimer's Research & Therapy 2023 15:24 -
Altered dynamics of glymphatic flow in a mature-onset Tet-off APP mouse model of amyloidosis
Alzheimer’s disease (AD) is an incurable neurodegenerative disorder characterised by the progressive buildup of toxic amyloid-beta (Aβ) and tau protein aggregates eventually leading to cognitive decline. Recen...
Citation: Alzheimer's Research & Therapy 2023 15:23 -
How does apolipoprotein E genotype influence the relationship between physical activity and Alzheimer’s disease risk? A novel integrative model
Wide evidence suggests that physical activity (PA) confers protection against Alzheimer’s disease (AD). On the other hand, the apolipoprotein E gene (APOE) ε4 allele represents the greatest genetic risk factor fo...
Citation: Alzheimer's Research & Therapy 2023 15:22 -
Clinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutation
Semantic variant primary progressive aphasia (svPPA) is generally sporadic, with very few reports of tau pathology caused by MAPT mutations.
Citation: Alzheimer's Research & Therapy 2023 15:21 -
The beneficial effect on cognition of noninvasive brain stimulation intervention in patients with dementia: a network meta-analysis of randomized controlled trials
Dementia [i.e., Alzheimer disease (AD)], the most common neurodegenerative disease, causes profound negative impacts on executive function and quality of life. Available pharmacological treatments often fail t...
Citation: Alzheimer's Research & Therapy 2023 15:20 -
Early visual alterations in individuals at-risk of Alzheimer’s disease: a multidisciplinary approach
The earliest pathological features of Alzheimer’s disease (AD) appear decades before the clinical symptoms. The pathology affects the brain and the eye, leading to retinal structural changes and functional vis...
Citation: Alzheimer's Research & Therapy 2023 15:19 -
Correction: Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
Citation: Alzheimer's Research & Therapy 2023 15:18 -
Convergent transcriptomic and genomic evidence supporting a dysregulation of CXCL16 and CCL5 in Alzheimer’s disease
Neuroinflammatory factors, especially chemokines, have been widely reported to be involved in the pathogenesis of Alzheimer’s disease (AD). It is unclear how chemokines are altered in AD, and whether dysregula...
Citation: Alzheimer's Research & Therapy 2023 15:17 -
A novel human tau knock-in mouse model reveals interaction of Abeta and human tau under progressing cerebral amyloidosis in 5xFAD mice
Hyperphosphorylation and intraneuronal aggregation of the microtubule-associated protein tau is a major pathological hallmark of Alzheimer’s disease (AD) brain. Of special interest is the effect of cerebral am...
Citation: Alzheimer's Research & Therapy 2023 15:16 -
Impact of atrial fibrillation on the cognitive decline in Alzheimer’s disease
Atrial fibrillation (AF) is a strong risk factor for Alzheimer’s disease (AD) independent of ischemic stroke. However, the clinicopathological impact of AF on the severity of AD has not been well elucidated. W...
Citation: Alzheimer's Research & Therapy 2023 15:15 -
The effects of imaging markers on clinical trajectory in cerebral amyloid angiopathy: a longitudinal study in a memory clinic
We investigated the relevance of various imaging markers for the clinical trajectory of cerebral amyloid angiopathy (CAA) patients in a memory clinic.
Citation: Alzheimer's Research & Therapy 2023 15:14 -
Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer’s disease: results from the DELCODE study
Neuroinflammation constitutes a pathological hallmark of Alzheimer’s disease (AD). Still, it remains unresolved if peripheral inflammatory markers can be utilized for research purposes similar to blood-based b...
Citation: Alzheimer's Research & Therapy 2023 15:13 -
The effects of a moderate physical activity intervention on physical fitness and cognition in healthy elderly with low levels of physical activity: a randomized controlled trial
Increasing physical activity is one of the most promising and challenging interventions to delay or prevent cognitive decline and dementia.
Citation: Alzheimer's Research & Therapy 2023 15:12 -
More extensive hypometabolism and higher mortality risk in patients with right- than left-predominant neurodegeneration of the anterior temporal lobe
Left-predominant neurodegeneration of the anterior temporal lobe (ATL) and the associated syndrome termed semantic variant primary progressive aphasia (svPPA) are well characterized. Less is known about right-...
Citation: Alzheimer's Research & Therapy 2023 15:11 -
Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer’s Disease (EPAD) cohort
The risk of dementia is higher in women than men. The metabolic consequences of estrogen decline during menopause accelerate neuropathology in women. The use of hormone replacement therapy (HRT) in the prevent...
Citation: Alzheimer's Research & Therapy 2023 15:10 -
Walking pace, handgrip strength, age, APOE genotypes, and new-onset dementia: the UK Biobank prospective cohort study
The independent and additive associations of walking pace and grip strength on dementia risk and the potential modifying effects of age, APOE phenotypes, and other dementia risk factors on the walking pace and...
Citation: Alzheimer's Research & Therapy 2023 15:9 -
Molecular insights into sex-specific metabolic alterations in Alzheimer’s mouse brain using multi-omics approach
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is characterized by altered cellular metabolism in the brain. Several of these alterations have been found to be exacerbated in females...
Citation: Alzheimer's Research & Therapy 2023 15:8 -
Leading mediators of sex differences in the incidence of dementia in community-dwelling adults in the UK Biobank: a retrospective cohort study
Little is known regarding whether sex assigned at birth modifies the association between several predictive factors for dementia and the risk of dementia itself.
Citation: Alzheimer's Research & Therapy 2023 15:7 -
Continuity of care (COC) and amyloid-β PET scan: the CARE-IDEAS study
High continuity of care (COC) is associated with better clinical outcomes among older adults. The impact of amyloid-β PET scan on COC among adults with mild cognitive impairment (MCI) or dementia of uncertain ...
Citation: Alzheimer's Research & Therapy 2023 15:6 -
Dementia and psychotropic medications are associated with significantly higher mortality in geriatric patients hospitalized with COVID-19: data from the StockholmGeroCovid project
Dementia and psychotropic medications are discussed as risk factors for severe/lethal outcome of the coronavirus disease 2019 (COVID-19). We aimed to explore the associations between the presence of dementia a...
Citation: Alzheimer's Research & Therapy 2023 15:5 -
Correction: Treatment needs of dementia with Lewy bodies according to patients, caregivers, and physicians: a cross-sectional, observational, questionnaire-based study in Japan
Citation: Alzheimer's Research & Therapy 2023 15:4 -
Altered metabolic connectivity within the limbic cortico-striato-thalamo-cortical circuit in presymptomatic and symptomatic behavioral variant frontotemporal dementia
Behavioral variant frontotemporal dementia (bvFTD) is predominantly considered a dysfunction in cortico-cortical transmission, with limited direct investigation of cortical-subcortical transmission. Thus, we a...
Citation: Alzheimer's Research & Therapy 2023 15:3 -
Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline
Accessible and cost-effective diagnostic tools are urgently needed to accurately quantify blood biomarkers to support early diagnosis of Alzheimer’s disease (AD). In this study, we investigated the ability of ...
Citation: Alzheimer's Research & Therapy 2023 15:2 -
Neuropsychological test performance of former American football players
Patterns of cognitive impairment in former American football players are uncertain because objective neuropsychological data are lacking. This study characterized the neuropsychological test performance of for...
Citation: Alzheimer's Research & Therapy 2023 15:1 -
Effects of non-modifiable risk factors of Alzheimer’s disease on intracortical myelin content
Non-modifiable risk factors of Alzheimer’s disease (AD) have lifelong effects on cortical integrity that could be mitigated if identified at early stages. However, it remains unknown whether cortical microstru...
Citation: Alzheimer's Research & Therapy 2022 14:202 -
Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer’s disease
Alpha-synuclein (α-syn) is considered the main pathophysiological protein component of Lewy bodies in synucleinopathies. α-Syn is an intrinsically disordered protein (IDP), and several types of structural conf...
Citation: Alzheimer's Research & Therapy 2022 14:201 -
Paroxysmal slow wave events are associated with cognitive impairment in patients with obstructive sleep apnea
Increasing evidence has supported a link between obstructive sleep apnea (OSA) and cognition, and blood-brain barrier (BBB) dysfunction which can be reflected by paroxysmal slow wave events (PSWEs) may be a po...
Citation: Alzheimer's Research & Therapy 2022 14:200 -
A low-dimensional cognitive-network space in Alzheimer’s disease and frontotemporal dementia
Alzheimer’s disease (AD) and frontotemporal dementia (FTD) show network dysfunctions linked with cognitive deficits. Within this framework, network abnormalities between AD and FTD show both convergent and div...
Citation: Alzheimer's Research & Therapy 2022 14:199 -
CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer’s disease
Efavirenz is an anti-HIV drug, and cytochrome P450 46A1 (CYP46A1) is a CNS-specific enzyme that metabolizes cholesterol to 24-hydroxycholesterol (24HC). We have previously shown that allosteric CYP46A1 activat...
Citation: Alzheimer's Research & Therapy 2022 14:198 -
Subjective cognitive decline is a better marker for future cognitive decline in females than in males
The identification of biomarkers for early detection of Alzheimer’s disease (AD) is critical to the development of therapies and interventions targeted at symptom management and tracking the pathophysiology of...
Citation: Alzheimer's Research & Therapy 2022 14:197 -
Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer’s disease brain extracts
In Alzheimer’s disease (AD), amyloid-β 1–42 (Aβ42) neurotoxicity stems mostly from its soluble oligomeric aggregates. Studies of such aggregates have been hampered by the lack of oligomer-specific research too...
Citation: Alzheimer's Research & Therapy 2022 14:196 -
The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review
The extracellular buildup of amyloid beta (Aβ) plaques in the brain is a hallmark of Alzheimer’s disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for identifying and recruiting researc...
Citation: Alzheimer's Research & Therapy 2022 14:195 -
ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer’s disease
Alzheimer’s disease (AD) shares risk factors with cardiovascular disease (CVD) and dysregulated cholesterol metabolism is a mechanism common to both diseases. Cholesterol efflux capacity (CEC) is an ex vivo me...
Citation: Alzheimer's Research & Therapy 2022 14:194 -
Synergistic interaction of high blood pressure and cerebral beta-amyloid on tau pathology
Hypertension has been associated with Alzheimer’s disease (AD) dementia as well as vascular dementia. However, the underlying neuropathological changes that link hypertension to AD remain poorly understood. In...
Citation: Alzheimer's Research & Therapy 2022 14:193 -
CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
Cerebrospinal fluid (CSF) tau biomarkers are reliable diagnostic markers for Alzheimer’s disease (AD). However, their strong association with amyloid pathology may limit their reliability as specific markers o...
Citation: Alzheimer's Research & Therapy 2022 14:192 -
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD....
Citation: Alzheimer's Research & Therapy 2022 14:191 -
Persisting neuropsychiatric symptoms, Alzheimer’s disease, and cerebrospinal fluid cortisol and dehydroepiandrosterone sulfate
Neuropsychiatric symptoms are important treatment targets in the management of dementia and can be present at very early clinical stages of neurodegenerative diseases. Increased cortisol has been reported in A...
Citation: Alzheimer's Research & Therapy 2022 14:190 -
Association of neurofilament light chain with renal function: mechanisms and clinical implications
Blood-based neurofilament light chain (NfL) is a promising biomarker of neurodegeneration across multiple neurodegenerative diseases. However, blood-based NfL is highly associated with renal function in older ...
Citation: Alzheimer's Research & Therapy 2022 14:189
Follow
- ISSN: 1758-9193 (electronic)